$5.02
$92 M
ZYNE Mkt cap, 15-Feb-2019Zynerba Pharmaceuticals Net income (Q3, 2018)-7.8 M
Zynerba Pharmaceuticals EBIT (Q3, 2018)-8 M
Zynerba Pharmaceuticals Cash, 30-Sep-201866.2 M
Zynerba Pharmaceuticals Income Statement
Annual
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 15.4k | 199.4k | 7.3k | ||||||||
R&D expense | 1.0m | 2.3m | 2.6m | 4.8m | 4.5m | 5.5m | 5.7m | 5.8m | 9.0m | 8.5m | 4.9m |
General and administrative expense | 631.5k | 1.9m | 1.7m | 1.5m | 1.5m | 2.2m | 2.6m | 2.8m | 3.4m | 3.4m | 3.1m |
Operating expense total | 1.6m | 4.2m | 4.2m | 6.3m | 6.0m | 7.7m | 8.4m | 8.5m | 12.4m | 12.0m | 8.0m |
EBIT | (1.6m) | (4.0m) | (4.2m) | (6.3m) | (6.0m) | (7.7m) | (8.4m) | (8.5m) | (12.4m) | (12.0m) | (8.0m) |
EBIT margin, % | (10572%) | (2004%) | (58509%) | ||||||||
Interest expense | 697.0 | 1.6k | |||||||||
Interest income | 697.0 | 1.6k | 12.4k | 18.1k | 22.7k | 76.9k | 124.5k | 161.9k | 175.2k | 186.3k | 278.2k |
Pre tax profit | (4.3m) | (6.3m) | (6.0m) | (7.3m) | (8.3m) | (8.3m) | |||||
Income tax expense | 28.7k | (56.3k) | |||||||||
Net Income | (1.6m) | (4.0m) | (4.3m) | (6.2m) | (6.0m) | (7.3m) | (8.3m) | (8.3m) | (12.3m) | (12.0m) | (7.8m) |
Zynerba Pharmaceuticals Balance Sheet
Annual
| USD | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Cash | 41.5m | 31.0m | 62.5m |
Current Assets | 43.4m | 36.4m | 68.2m |
PP&E | 227.6k | 143.4k | 164.5k |
Total Assets | 43.6m | 36.6m | 69.1m |
Accounts Payable | 823.4k | 1.8m | 3.4m |
Current Liabilities | 3.9m | 7.0m | 7.4m |
Total Liabilities | 8.1m | ||
Additional Paid-in Capital | 62.3m | 75.5m | 138.9m |
Retained Earnings | (22.6m) | (46.0m) | (78.0m) |
Total Equity | 39.7m | 29.6m | 60.9m |
Financial Leverage | 1.1 x | 1.2 x | 1.1 x |
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 5.7m | 44.8m | 36.8m | 32.1m | 31.8m | 77.5m | 70.2m | 66.3m | 52.1m | 43.1m | 66.2m |
Current Assets | 9.4m | 46.9m | 38.5m | 35.6m | 35.5m | 83.4m | 76.5m | 72.9m | 58.0m | 49.0m | 72.7m |
PP&E | 103.9k | 229.0k | 223.2k | 209.3k | 304.1k | 198.2k | 178.0k | 190.4k | 155.3k | 273.8k | 248.7k |
Total Assets | 9.5m | 47.1m | 39.1m | 35.8m | 36.3m | 84.7m | 79.1m | 73.1m | 59.9m | 52.2m | 72.9m |
Accounts Payable | 1.8m | 615.5k | 989.4k | 2.7m | 1.7m | 996.9k | 2.0m | 3.1m | 4.6m | 6.4m | 3.6m |
Current Liabilities | 4.1m | 2.7m | 2.9m | 5.0m | 4.9m | 6.9m | 7.9m | 8.4m | 8.9m | 11.3m | 9.1m |
Total Liabilities | 5.4m | 9.6m | 12.1m | 9.1m | |||||||
Additional Paid-in Capital | 2.0m | 61.5m | 63.0m | 63.9m | 69.9m | 131.0m | 132.8m | 134.5m | 140.6m | 142.4m | 173.9m |
Retained Earnings | (13.1m) | (17.1m) | (26.9m) | (33.1m) | (39.1m) | (53.2m) | (61.6m) | (69.9m) | (90.3m) | (102.3m) | (110.1m) |
Total Equity | (11.2m) | 44.4m | 36.2m | 30.8m | 30.9m | 77.8m | 71.2m | 64.6m | 50.3m | 40.1m | 63.8m |
Financial Leverage | -0.8 x | 1.1 x | 1.1 x | 1.2 x | 1.2 x | 1.1 x | 1.1 x | 1.1 x | 1.2 x | 1.3 x | 1.1 x |
Zynerba Pharmaceuticals Cash Flow
Annual
| USD | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Net Income | (12.6m) | (23.4m) | (32.0m) |
Depreciation and Amortization | 26.0k | 75.3k | 94.2k |
Accounts Payable | 536.4k | 1.0m | 1.5m |
Cash From Operating Activities | (9.8m) | (20.4m) | (25.8m) |
Purchases of PP&E | (216.3k) | (109.6k) | (115.4k) |
Cash From Investing Activities | (216.3k) | (109.6k) | (115.4k) |
Cash From Financing Activities | 42.2m | 10.0m | 57.5m |
Quarterly
| USD | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (3.1m) | (7.1m) | (4.3m) | (10.5m) | (16.5m) | (7.3m) | (15.6m) | (23.9m) | (12.3m) | (24.3m) | (32.1m) |
Depreciation and Amortization | 4.5k | 12.8k | 13.6k | 27.5k | 53.3k | 20.4k | 43.6k | 68.4k | 26.6k | 48.2k | 73.2k |
Accounts Payable | 761.9k | 1.3m | 185.5k | 1.9m | 687.4k | (851.2k) | 122.4k | 1.2m | 1.3m | 2.9m | 121.6k |
Cash From Operating Activities | (3.5m) | (6.6m) | (4.7m) | (9.4m) | (14.9m) | (7.6m) | (15.3m) | (19.1m) | (10.4m) | (19.3m) | (26.2m) |
Purchases of PP&E | (46.3k) | (176.1k) | (28.5k) | (28.5k) | (86.7k) | (68.6k) | (78.2k) | (91.1k) | (17.4k) | (117.6k) | (157.4k) |
Cash From Investing Activities | (46.3k) | (176.1k) | (28.5k) | (28.5k) | (86.7k) | (68.6k) | (78.2k) | (91.1k) | (17.4k) | (117.6k) | (157.4k) |
Cash From Financing Activities | (53.6k) | 42.2m | 5.3m | 54.2m | 54.6m | 54.5m | 30.0m |
Zynerba Pharmaceuticals Ratios
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Report incorrect company information
